INHIBITORS OF MENIN-MLL INTERACTION Russian patent published in 2024 - IPC C07D471/00 C07D487/04 A61K31/437 A61K31/519 A61P35/00 

FIELD: chemistry.

SUBSTANCE: invention relates to a compound of formula I or a pharmaceutically acceptable salt thereof, where ring A is a group of formulas given in the claim, where e and f denote points of attachment of the remaining part of the molecule; U is N or CR^U, where R^U is H; group (a) is selected from (a1), (a2), (a3), (a4) or (a5), where R^Y is H; X is F or Cl; L is selected from -C_1-6 alkylene- and -(C_1-4 alkylene)_a-Q-(C_1-4 alkylene)_b-, where C_1-6 alkylene group and any C_1-4 alkylene group from -(C_1-4 alkylene)_a-Q-(C_1-4 alkylene)_b-group is optionally substituted with 1, 2 or 3 substitutes independently selected from C_1-3 alkyl; Q is -O-, -NR^q1-, C(=O) or -C(=O)NR^q1-, where each R^q1 is independently selected from H and C_1-6 alkyl; Cy is a group of formulas (given in the claim), each of which is optionally substituted with 1, 2, 3 or 4 substituents independently selected from R^Cy; each R^Cy is independently selected from halogen, C_1-6 alkyl, C_1-4 haloalkyl, C_1-4 cyanoalkyl, CN, OR^a1, C(O)NR^c1R^d1, C(O)OR^a1, NR^c1S(O)₂R^b1, NR^c1R^d1, NR^c1C(O)R^b1, NR^c1C(O)OR^a1 and S(O)₂R^b1, where said radicals are optionally substituted with 1 or 2 substituents independently selected from OR^a1, OC(O)R^b1 and C(O)OR^a1; R¹ is H, OR^a2, NR^c2R^d2 or C_1-6 alkyl; Z is OR^a3 or C(O)NR^c3R^d3; each R², R³, R⁴ and R⁵ independently represents H; each R^a1, R^b1, R^c1, R^d1, R^a2, R^c2, R^d2, R^a3, R^c3 and R^d3 is independently selected from H, C_1-6 alkyl and C_3-10 cycloalkyl-C_1-6 alkyl, where said C_1-6 alkyl and C_3-10 cycloalkyl-C_1-6 alkyl, each optionally substituted with 1, 2, 3, 4 or 5 substitutes independently selected from R^g; each R^g is OH; n is 0 or 1; m is 0 or 1; p is 0, 1, 2 or 3; r is 0, 1 or 2; a has value of 0 or 1; and b is 0 or 1, where any cycloalkyl or heterocycloalkyl group is optionally further substituted with 1 or 2 oxo groups. Invention also relates to specific compounds. Invention relates to a pharmaceutical composition which inhibits the interaction between menin and MLL, comprising a therapeutically effective amount of a compound according to the invention or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier. Compounds according to the invention are intended for use in preparing a drug for inhibiting the interaction between menin and MLL.

EFFECT: inhibitors of interaction of menin with MLL and MLL fusion proteins.

47 cl, 16 tbl, 1 dwg, 142 ex